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Abstract 
Background/Aims: Calciphylaxis is associated with a poor prognosis in dialysis 
patients, and its pathogenesis remains incompletely understood. Although the use of 
vitamin K antagonists (VKA) has been implicated, previous reports are conflicting. 
We aimed to determine if vitamin K antagonists conferred an increased risk of 
calciphylaxis in patients on dialysis. Methods: We performed a single-centre, 
retrospective cohort study of 2,234 patients receiving dialysis, and compared 
characteristics of those with and without calciphylaxis. Results: We identified 5 cases 
of calciphylaxis (all female) between January 2009 and December 2013. Overall, 142 
patients (6.4%) were treated with VKA during the study period. Calciphylaxis was 
more common in the VKA group (4 of 142 patients, OR = 61, 95% CI 6.7 – 546, 
p=0.0001). VKA was withdrawn in all cases and treatment instituted with sodium 
thiosulphate, cinacalcet and supportive measures. All patients recovered, although 
there was one sudden cerebrovascular death during follow-up. Conclusion: 
Treatment with VKA predisposes to the development of calciphylaxis.  
 
Background and Introduction 
Calciphylaxis, also known as calcific uremic arteriolopathy (CUA), is a serious 
condition affecting small arterioles. It is characterised by vascular calcification, 
intimal hyperplasia and microthrombi, with secondary fat necrosis [1]. Clinically this 
gives rise to painful cutaneous purpuric plaques and nodules with ulceration [2]. 
Calciphylaxis carries a poor prognosis. Previous studies report a 1-year survival of 
less than 50%, with the majority of deaths occurring from sepsis or cardiovascular 
events [3,4]. Calciphylaxis occurs most commonly in end-stage renal disease (ESRD) 
requiring dialysis, but is also associated with primary hyperparathyroidism, 
malignancy, connective tissue disorders and the use of vitamin K antagonists (VKA). 
Other risk factors include diabetes, female gender, obesity and thrombophilia 
syndromes such as protein C and S deficiency [5]. However, even in the setting of 
ESRD, where calciphylaxis is most commonly described, it is a rare disease with an 
estimated prevalence of up to 5.7 per 10,000 haemodialysis patients [4,6]. 
The pathophysiology of calciphylaxis is incompletely understood. Extracellular fluid 
is supersaturated with calcium and phosphate, but precipitation and crystallization 
does not usually occur due to the presence of calcification inhibitors. Excessive 
calcium and phosphate concentrations such as commonly occur in renal failure can 
result in direct tissue precipitation, or may promote arteriolar calcification through 
osteogenic transformation of vascular smooth muscle cells [7]. Parathyroid hormone 
(PTH) is central to calcium and phosphate homeostasis, and perturbations in PTH 
concentrations may contribute to the development of calciphylaxis [8]. Other potential 
modulators of calcification include the NFκB pathway, the transcription factor Cbfa-
1, and inhibitors of calcification including Fetuin-A and Matrix-Gla-protein (MGP) 
[4,9,10]. MGP has attracted particular interest given its potent inhibition of vascular 
calcification and requirement for vitamin K dependent gamma-carboxylation. Since 
MGP gamma-carboxylation status is impaired in haemodialysis patients [9,10], and 
VKA treatment reduces MGP gamma-carboxylation and promotes medial arterial 
calcification [11,12], VKA use may also predispose to the development of 
calciphylaxis. However, data from existing studies are conflicting [4,13-16]. 
We hypothesized that the use of VKAs in dialysis patients would be associated with 
an increased incidence of calciphylaxis. We therefore carried out a single centre 
cohort study to determine the predictors of calciphylaxis and the effect of treatment 
with VKAs. 
 
Methods 
Data 
All patients who received renal replacement therapy at Addenbrooke’s Hospital, 
Cambridge, between 1
st
 January 2009 and 31
st
 December 2013 were considered for 
the study. Patients were included if they had received haemodialysis or peritoneal 
dialysis during the study period. Patients were excluded if they had received acute 
dialysis (<90 days duration) only. Demographic and laboratory data were abstracted 
from the hospital’s electronic database system, including age, gender, date of dialysis 
initiation, diabetic status, date of death, prescribing history, parathyroid hormone 
(PTH), albumin, calcium, phosphate, sodium, haemoglobin, and coagulation studies 
including INR. Biochemical and haematological data for 6 months before and after 
the study window were included. 
Cases of calciphylaxis were identified from hospital and local histopathology records. 
Albumin-corrected calcium [normal range 2.1 – 2.5 mmol/l], phosphate [normal range 
0.8 – 1.4 mmol/l], and creatinine [normal range 35 - 125 μmol/l] were analysed using 
a Dimension® auto-analyser (SIEMENS Ltd.). Hyper- or hypophosphataemia, or -
calcaemia, was defined as corrected calcium or phosphate values above or below the 
respective reference ranges noted above. PTH [normal range 14 – 72 ng/l] was 
analysed using the ADVIA® Centaur XP Immunoassay system for intact PTH (1-84) 
(SIEMENS Ltd.). 
 
Analysis 
Data are presented as mean (SD) or median (interquartile range) as appropriate. 
Comparisons for demographic data between calciphylaxis cases and controls were 
made by student’s T-test or Mann-Whitney rank sum test for continuous variables and 
Fisher’s exact test for frequency data. The odds ratios, point estimates and confidence 
intervals for developing calciphylaxis were computed by exposure to vitamin K 
antagonists, using Woolf’s method [17]. All analyses were carried out using Stata SE 
v 13.1, College Station TX. 
 
Results 
Between 1 January 2009 and 31 December 2013, 2,234 patients received dialysis at 
our centre, representing 8,504 patient years follow-up. Of these, 289 received 
peritoneal dialysis during the study period. Median dialysis vintage at the end of 
follow-up was 3.0 (1.1 – 5.3) years. During the study period, 142 patients (6.4%) 
were treated with VKA, of whom 141 received warfarin, and 1 acetocoumarol. VKA-
treated patients were significantly older (p=0.02), and had shorter follow-up times 
(1275, IQR 687 – 1860 days) than controls (1786, IQR 944 – 1897 days, p<0.0001). 
There were more deaths (40/142 (28%) versus 429/2092 (20%)) in the VKA-treated 
group (p=0.03). 
Calciphylaxis was diagnosed in 5 patients (all female) during the study period. 
Characteristics of calciphylaxis cases are summarized in Table 1. Diagnosis was 
histologically confirmed in all cases (representative example for patient 3 shown in 
Figure 1). In comparison with the control population, calciphylaxis patients had 
similar calcium (2.38 ± 0.25 versus 2.23 ± 0.22 mmol/l, p=0.11), phosphate (1.46 ± 
0.26 versus 1.24 ± 0.49 mmol/l, p=0.3) PTH (172 (IQR 39-190) versus 115 (IQR 51 – 
232) ng/l, p=0.99) and CRP concentrations (45 (34-52) versus 18 (5-58), p=0.22). In 
the warfarin group, 4 calciphylaxis cases occurred in 142 patients; in the control 
group, 1 case occurred in 2092 patients. Although the overall incidence was low 
(0.0005 per patient year), the incidence was significantly higher in patients receiving 
vitamin K antagonists (0.008 per patient year, OR = 61, 95% CI 6.7 – 546, p=0.0001).  
 
Case Descriptions 
 
Patient 1 
A 75-year-old female haemodialysis patient developed several painful, indurated 
areas over the infra-umbilical anterior abdominal wall. She had received warfarin for 
4 years for recurrent deep vein thrombosis. Ultrasound demonstrated nodular 
hyperechoic areas in subcutaneous tissue, and needle biopsy confirmed calciphylaxis. 
Marked secondary hyperparathyroidism was present, and had been treated for 12 
months with the calcimimetic cinacalcet (180mg per day at diagnosis). 
Treatment was instituted with intradialytic sodium thiosulphate (STS) along with 
continued cinacalcet use, and warfarin convereted to dabigatran. Subtotal 
parathyroidectomy was carried out 3 months later following identification of a left-
sided parathyroid adenoma. The patient made a full recovery with complete resolution 
of symptoms, although abdominal wall lesions remain palpable. 
 
Patient 2 
A 69-year-old female type II diabetic haemodialysis patient presented with abdominal 
wall pain and multiple small areas of cutaneous infarction. A biopsy of one of the 
lesions revealed calciphylaxis. The patient had diabetic microvascular disease 
including retinopathy, peripheral neuropathy and nephropathy, and had received 
warfarin for two-and-a-half years for recurrent deep venous thrombosis (without 
evidence of a thrombopylia disorder). 
Treatment consisted of intradialytic STS, substitution of calcium-based phosphate 
binders with sevelamer-HCl, cinacalcet 30mg once daily, and substitution of warfarin 
with dalteparin. STS was limited to 5 treatments due to severe nausea and vomiting; 
dalteparin was converted to dabigatran due to hair loss. The lesions healed completely 
over a period of approximately 3 months, and the patient remained well for a further 
three months before suffering a fatal brain stem infarction secondary to basilar artery 
thrombosis. 
 
Patient 3 
A 45-year-old female dialysis patient received a third successful renal transplant in 
January 2013 after 8 years on haemodialysis, with stable primary graft function 
(eGFR 30ml/min/1.73m
2
 after several weeks). She had developed tertiary 
hyperparathyroidism and received a subtotal parathyroidectomy before 
transplantation, but became hypercalcaemic 6 weeks after transplantation and 
developed painful nodular skin lesions over the right breast and both upper arms. A 
skin biopsy from the right deltoid region revealed features of calciphylaxis (Figure 1). 
She had received warfarin for 4 years up to the time of transplantation for recurrent 
deep venous thrombosis. 
Calciphylaxis and hypercalcaemia were treated with intravenous STS, pamidronate 
30mg weekly, sevelamer-HCL, and analgesia. The patient had a difficult course with 
severe pain and progressive lesions requiring surgical debridement, followed by poor 
wound healing and necrosis ultimately requiring mastectomy. Although new lesions 
continued to emerge up to 6 months after diagnosis, these had improved after 9 
months and ultimately healed, with the patient making a full recovery. 
 
Patient 4 
A 64-year-old female haemodialysis patient presented with painful lesions over the 
abdominal wall and breasts, 6 years after commencing warfarin treatment for 
recurrent pulmonary emboli in the context of a positive lupus anticoagulant. She had 
presented two years previously with similar lesions but inconclusive histology and 
subsequent spontaneous improvement (although incomplete resolution). One year 
after the initial presentation, surgical debridement of abdominal lesions was 
undertaken. Retrospective review of surgical excision biopsies demonstrated features 
consistent with calciphylaxis.  
Treatment included cinacalcet, substitution of calcium acetate with sevelamer, and 
substitution of warfarin with dabigatran. Given the severity of symptoms, several 
lesions were resected. The patient made a full recovery. Cinacalcet was eventually 
discontinued after 9 months due to oversuppression of PTH. The patient remains 
asymptomatic. 
 
Patient 5 
A 73-year-old female haemodialysis patient with peripheral vascular disease and 
previous left above-knee amputation developed painful ulceration of the amputation 
stump. The ulceration did not resolve with conservative management and an empirical 
course of prednisolone, and a skin biopsy demonstrated calciphylaxis. Renal failure 
was attributed to nephrocalcinosis of unknown aetiology. Marked secondary 
hyperparathyroidism had resulted in hypercalcaemia at the time of diagnosis.  
Treatment consisted of post-dialytic STS, cinacalcet 60mg per day, and sevelamer-
HCl. Lesions showed slow resolution over a period of 4 months. Subtotal 
parathyroidectomy was undertaken three months after presentation. The patient made 
a full recovery. 
 
Patient characteristics are summarised in detail in supplementary table 1. 
 
Discussion 
Calciphylaxis is a serious complication in patients with advanced renal impairment, 
with a reported mortality of up to 81% and a median post-diagnosis survival of less 
than 3 months.[4] Here, we identified 5 cases of calciphylaxis in a large cohort of 
dialysis patients over a 5-year study period, 4 of whom had received treatment with 
vitamin K antagonists prior to diagnosis. Further, we report a good outcome in all 
patients (except for one sudden cerebrovascular death) after treatment with STS, 
calcimimetics, and the withdrawal of vitamin K antagonists. 
Previous reports have implicated VKAs in the development of calciphylaxis. In 
addition to many anecdotal reports [13-15,18], Nigwekar et al. reported a strong 
association with warfarin use (OR = 4.3) in a case control study including 62 cases of 
calciphylaxis [15]. In contrast, Weenig et al. reported high usage of warfarin, but no 
association with calciphylaxis in 64 cases and 98 matched controls [4]. Similarly, 
Fine and Zacharias reported no association of warfarin use with calciphylaxis in a 
case-control study of 36 cases with calciphylaxis, although this study had 
methodological shortcomings [16]. Our findings support an association of 
calciphylaxis with warfarin use. Together with evidence that VKA use is also 
associated with large vessel calcification (itself a predictor of mortality) [12], and that 
warfarin use increases bleeding risk and does not prevent cerebrovascular events in 
patients receiving dialysis [19], our findings provide a rationale for limiting exposure 
to VKAs in ESRD. 
All cases identified were post-menopausal females. This finding is consistent with the 
female preponderance reported in most other studies [4,15,20], where 64 – 80% of 
cases are female; Mazhar and colleagues reported an odds ratio of 6.04 [2]. The 
mechanism underlying this excess risk is likely to be associated with oestrogen 
deficiency, which increases the risks of osteoporosis and vascular calcification [8] and 
results in reduced expression of osteoprotegerin [8]. One patient (patient 3) developed 
calciphylaxis post-transplantation. Although calciphylaxis is unusual in this setting, 
she had a high dialysis vintage (95 months) and had developed severe tertiary 
hyperparathyroidism pre-transplantation. Histology was consistent with a diagnosis of 
calciphylaxis (Figure 1). 
Our study has several strengths. First, we present data from a large contemporary 
dialysis cohort. Second, all cases were confirmed histologically, and data on the use 
of VKA were recorded routinely. Third, outcome data were available on all patients. 
However, our findings should be considered against the limitations of our study, 
including the small number of cases and its retrospective nature. 
Patients with ESRD often require systemic anticoagulation for atrial fibrillation or 
recurrent venous thrombo-embolism, and some physicians continue to use warfarin 
for maintenance of vascular access patency. Our data demonstrate that, where 
continued anticoagulation is required, the use of newer anticoagulants such as 
dabigatran in conjunction with STS, cincacalcet, avoidance of oral calcium intake and 
definitive treatment of resistant hyperparathyroidism can results in resolution of 
cutaneous lesions. Our findings add to a growing body of evidence that supports the 
avoidance of VKA treatment in patients with ESRD. Where calciphylaxis does occur, 
VKAs should be withdrawn. 
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Fig. 1. Patient 3. Arterioles in subcutis showing mural calcification and luminal 
occlusion by fibrous intimal proliferation. There is surrounding fat necrosis (H&E 
stain). 
Table 1 
 Vitamin K 
Antagonists 
Control Total p-value 
n 142 2092 2234  
Age (years) 51 ± 12 47 ± 13 48 ± 14 0.02 
Male (%) 89 (63) 1443 (69) 1532 (64) 0.38 
Peritoneal dialysis 
(%) 
24 (17) 265 (13) 289 (13) 0.15 
Dialysis vintage (at 
last follow-up, days) 
1111 (623 – 
1826) 
1106 (348 – 
1943) 
1107 (400 – 
1933) 
0.45 
Follow-up time (days) 1275 (687 – 
1860) 
1786 (944 – 
1897) 
1753 (926 – 
1897) 
<0.0001 
Deaths (%) 40 (28%) 429 (20.5) 469 (21) 0.03 
Calciphylaxis (%) 4 (3) 1 (0.04) 5 0.0001 
 
 
 
Supplementary table 1 
Patient 
characterist
ics 
Patient 
1 
Patient 
2 
Patient 3 Patient 
4 
Patient 
5 
Case 
Mean/Medi
an 
Age at 
Diagnosis 
(years) 
75 69 46 64 73 66 ± 12 
Gender  Female Female Female Female Female  
Dialysis 
Vintage 
(months) 
22 3 95 4 47 22 (4 - 47) 
Kt/V 2.06 3.8 1.72* 1.6 1.75 2.2 ±  0.9 
URR (%) 73 71 79* 76 78 74.4 ± 3.8 
Dialysis 
frequency 
(per week) 
3 3 - 3 3 3 
Primary 
renal disease 
Htn DN CPN Unknow
n 
Unknow
n 
- 
Vascular 
comorbiditie
s 
- PVD, 
HF 
- - PVD, 
IHD 
- 
Radiological 
evidence of 
arterial 
calcification 
Aorta 
Coronar
y  
Aorta 
Iliac 
Aorta 
Coronary  
Iliac 
Aorta 
Coronar
y 
Aorta 
Coronar
y 
Mesente
ric 
Iliac 
- 
Diabetes 
(treatment) 
- Insulin - - - - 
Hypertensio
n treatment 
(no of drugs) 
0 2 1 0 0 - 
Phosphate 
binders 
Calcium 
carbonat
e 
Calcium 
acetate 
Sevelame
r 
Calcium 
acetate 
Calcium 
acetate 
- 
Anticoagulat
ion 
Warfarin Warfari
n 
Warfarin Warfarin - 4/5 
Gout + - - - - - 
CRP 34 82 52 45 11 45 ± 26 
Corrected 
Calcium 
2.3 2.22 2.39 2.19 2.79 2.38 ± 0.24 
Phosphate 1.76 1.48 1.68 1.16 1.24 1.46 ± 0.26 
PTH 414 172 18 37 180 172 (37 - 
190) 
Post-Diagnosis Management and Outcomes 
STS Yes Yes Yes - Yes - 
Cinacalcet  60mg/d 30mg/d - 30mg/d 30mg/d - 
Anticoagulat
ion 
Dabigatr
an 
Daltepar
in 
- Dabigatr
an 
- - 
Phosphate 
binders 
Sevelam
er 
Sevelam
er 
Sevelame
r 
Sevelam
er 
Sevelam
er 
- 
Antimicrobia
l treatment 
- - Yes No  - 
Other - - Pamidron
ate 
- PTX - 
Survival 
after 
diagnosis 
(months) 
30 7 23 51 42 30 ± 17 
Cause of 
death 
- Brain 
stem 
infarct 
- - -  
Results for biochemical analyses shown represent values at diagnosis for cases, and 
averaged values over the observation period for control patients. PTX – 
parathyroidectomy. *Patient 3 presented post-transplantation. Values represent the 
last pre-transplantation values. 
